APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Running, not enrolling

Conditions studied: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic

In brief

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

Key facts

Study ID
NCT03615235
Run by
Wake Forest University Health Sciences
People needed
5000
Starts
2019-03-21
Expected to finish
2027-05-30
Last updated by the study team
2026-05-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.